Skip to content
Signal Bureau What’s happening · what the record shows

Egfr

A topic on our watch list — we track its coverage across 9 domains, including Pubmed Targeted, Preprint and Industry News.

Coverage of Egfr is holding steady : 4 signals on the latest tracked day, level with its three-week baseline of 4, across 3 domains. That makes it the #223 most-covered of the 348 concerns we track.

What’s changed

What the reporting says

It shows up alongside Colorectal Cancer (50), KRAS (27 — acquisition ×2), Braf (24 — acquisition ×2), Lung Cancer (23 — acquisition ×2), Immunotherapy (18), Her2 (15), ctDNA (9), FDA (14).

Two steps out: MSI-H (through Colorectal Cancer, 50 shared stories on the weaker link); Wang (through Colorectal Cancer, 50 shared stories on the weaker link); Zhang (through Colorectal Cancer, 50 shared stories on the weaker link); Chen (through Colorectal Cancer, 46 shared stories on the weaker link).

Tracked since Jan 1, with coverage on 58 separate days — concentrated in Oncology and Pubmed Targeted.

Ask the engine about Egfr + Track Egfr for a daily read
Counts computed from our committed signal record (Aug 20 – Aug 20, 1 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Sep 4, 8:23 PM PT